Heatwurx (NASDAQ:PCSA) Trading Up 10.5% – What’s Next?

Heatwurx Inc. (NASDAQ:PCSA) was up 10.5% on Thursday . The stock traded as high as $2.73 and last traded at $2.64. Approximately 110,559 shares were traded during trading, an increase of 107% from the average daily volume of 53,320 shares. The stock had previously closed at $2.39.

Analysts Set New Price Targets

Several equities research analysts have weighed in on PCSA shares. Wall Street Zen cut Heatwurx from a “hold” rating to a “sell” rating in a research note on Saturday, February 14th. Weiss Ratings reissued a “sell (e+)” rating on shares of Heatwurx in a research note on Tuesday, April 21st. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $25.00.

Heatwurx Price Performance

The company has a 50-day simple moving average of $2.71 and a 200-day simple moving average of $3.58. The firm has a market cap of $7.04 million, a PE ratio of -0.28 and a beta of 1.01.

Heatwurx Company Profile

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers.